Bacteraemia and antimicrobial susceptibility in dogs

Are multiple blood cultures advantageous for canine patients?

Successful treatment of bacteremic patients depends largely on timely detection of blood-borne pathogens. Failure to detect an infection and/or contamination of blood samples can substantially delay the proper treatment. To increase the detection rate of blood-borne pathogens, well-established guidelines on blood collection and processing have been practiced in human medicine. Investigations involving human blood cultures have shown that the multiple blood sample approach significantly improves the detection rate of bacterial pathogens in the blood. Unfortunately, veterinary-specific blood culture guidelines have not been defined. Therefore, we compared detection rates of blood-borne pathogens between single and multiple blood culture approaches in a retrospective study of the clinical data from canine blood culture cases. We analyzed the data that had been collected over ~6 y and 8 mo from 177 dogs admitted to a veterinary medical teaching hospital. The triple blood culture approach increased the detection rate of blood-borne pathogens by 19.5% compared to single sampling. The optimal timing between multiple sample collections remains to be determined.

First report of multiresistant, mecA-positive Staphylococcus intermedius in Europe: 12 cases from a veterinary dermatology referral clinic in Germany

Resistance to cephalosporins and/or fluoroquinolones by Staphylococcus intermedius has remained low in Europe, with effective drugs generally available for systemic therapy in pets. However, multiresistant, mecA-positive S. intermedius isolated from dogs and cats is now emerging in Europe. Twelve S. intermedius isolates, highly resistant to at least five antimicrobial classes, were isolated from skin and ear infections in 11 dogs and a cat. The 12 isolates represented 23% of all S. intermedius submissions from one veterinary dermatology referral clinic in northern Germany to veterinary diagnostic laboratories during an 18-month period and resistance included cefalexin, methicillin and enrofloxacin. The animals had been referred to the clinic with recurrent superficial pyoderma, deep pyoderma, pododermatitis or chronic otitis, all unresponsive to systemic beta-lactam-antibiotics or fluoroquinolones. Infection resolved in 10 dogs and the cat on a combination of antimicrobial treatment and correction of underlying causes. Four dogs and a cat required systemic and topical therapy; in six dogs topical antimicrobial therapy alone was successful. Phenotypic and genotypic characteristics of the S. intermedius isolates were determined; species identification was confirmed by polymerase chain detection of thermonuclease genes (nuc) and the presence and expression of the gene conferring resistance to all beta-lactam antibiotics (mecA) were demonstrated in all; based on pulsed-field gel electrophoresis, six were indistinguishable, the others closely or possibly related. The emergence of multiresistant, mecA-positive S. intermedius in Europe is alarming. Zoonotic implications, awareness among veterinary laboratories and strategies for the use of antimicrobials in small animal practice need to be considered.

Bacteraemia in 66 cats and antimicrobial susceptibility of the isolates (1995–2004)

Bacterial blood culture results of 292 privately owned cats presented to the Clinic for Small Animal Medicine, Ludwig Maximilian University Munich with signs of sepsis were evaluated retrospectively. Of the blood cultures, 23% were positive. In 88%, a single bacterial species was isolated. Of all bacterial isolates, 45% were Gram-positive, 43% were Gram-negative, and 12% were obligate anaerobes. The most frequently isolated bacteria were Enterobacteriaceae, obligate anaerobic species, Staphylococcus species and Streptococcus species. Of the cats with positive blood cultures, 32% were pretreated with antibiotics. Of all bacterial isolates, 77% were susceptible to enrofloxacin, 69% to chloramphenicol, 67% to gentamicin, and 64% to amoxycillin clavulanic acid. Only enrofloxacin reached an in vitro efficacy of more than 70% against Gram-positive and more than 74% against Gram-negative bacteria.